are at the core
of what we do.
We’d like to express our appreciation for the patients who have previously participated or are currently enrolled in our clinical trials. Your contributions will help others as a result of the knowledge gained from your participation.
RBT-1 (stannic protoporfin/iron sucrose) is a novel product that is given to patients one time via IV infusion, 24-48 hours prior to them undergoing cardiothoracic surgery. It has been shown in Phase 2 studies to protect against postoperative surgical complications (extended ICU stay, intubation, hospital stay and readmission rate).